Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation

J. Nemunaitis, F. R. Appelbaum, J. W. Singer, K. Lilleby, S. Wolff, J. P. Greer, P. Bierman, D. Resta, M. Campion, D. Levitt, Z. Zeigler, C. Rosenfeld, R. K. Shadduck, C. D. Buckner

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Recombinant human interleukin-3 (rhIL-3) was administered to 30 patients undergoing autologous bone marrow transplant (ABMT) for treatment of lymphoma. In this phase I dose escalation study, rhIL-3 was administered from day 0 to 20 after ABMT by 2-hour intravenous infusion at dose levels of 1, 2, 5, and 10 μg/kg/d. Seventeen patients did not complete therapy with rhIL-3. Eleven requested early discontinuation for malaise,6 confusion,1 transplant complications,3 or rapid engraftment1 and were removed from the study, whereas six patients developed grade III toxicity, including fever (three patients), or headache (three patients) possibly attributable to rhIL3. Other common toxicities included diarrhea, rigors, mucositis, and rash. The maximum tolerated dose of rhIL-3 was 2 μg/kg/d. No evidence of earlier hematopoietic cell recovery was observed compared with similar historical patients treated with recombinant human granulocyte-macrophage colony-stimulating factor. Future trials will be needed to determine alternate schedules of administration of rhIL-3 or the use of rhIL-3 in combination or in sequence with other growth factors.

Original languageEnglish (US)
Pages (from-to)3273-3278
Number of pages6
JournalBlood
Volume82
Issue number11
StatePublished - Jan 1 1993

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Nemunaitis, J., Appelbaum, F. R., Singer, J. W., Lilleby, K., Wolff, S., Greer, J. P., Bierman, P., Resta, D., Campion, M., Levitt, D., Zeigler, Z., Rosenfeld, C., Shadduck, R. K., & Buckner, C. D. (1993). Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood, 82(11), 3273-3278.